The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Yes I am in the same boat as several others and these posts have brought back memories both good, bad and ecstatic. Coming up for my 1st anniversary. I was spiked at 72p I think early April, bought more in the 50s and then in the 30s. Carried on buying up to 225 after P2 results and loaded up at 189 and then doubled up at 175 in the share issue. Last little top up in the 80s in November and December. So, current average about 130 with over 30% of my life savings in here.
I have definitely been through the mill with the SP and emotions but agree that this treatment should be a fantastic anti-viral in the doctors tool kit for many years to come. Let's hope so for the sake of humanity if nothing else.
Best to all
Spinnaker
Well done Woody. I am sure you have made the right decision.
I have had my first dose of Pfizer 5 weeks ago. That means I should be getting my second about the end of April/beginning of May. However a lot of people received their first jabs in the weeks before I did and I wonder if lack of vaccines will screw up second dose timings. That is probably what they are worried about but not a dicky bird from Matt Handjob on second doses today. No doubt that is why they are delaying under 50s now.
Spinnaker
The P2 is listed on the linked site as is the P3 dated 12 November 2020 pasted below but format may be rubbish. I must say it is like wading through treacle. I did a search for 'Covid 19 AND treatment AND Synairgen' and they popped up. Link https://www.clinicaltrialsregister.eu/ctr-search/search?query=covid-19+AND+treatment+AND+Synairgen
Best Spinnaker
EudraCT Number: 2020-004743-83 Sponsor Protocol Number: SG018 Start Date*: 2020-11-09
Sponsor Name:Synairgen Research Limited
Full Title: A randomised, double-blind, placebo-controlled, Phase III trial to determine the efficacy and safety of inhaled SNG001 for the treatment of patients hospitalised due to moderate COVID-19
Medical condition: COVID-19
Disease: Version SOC Term Classification Code Term Level
23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: GB (GB - no longer in EU/EEA) PT (Ongoing)
Trial results: (No results available)
I assume that Mologic are still working with Avacta and the agreement with Aptamer will not affect Avacta's relationship. See extract from RNS 8 February below
'Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented:
"I am very pleased to announce this partnership with Mologic, which follows a close collaboration over recent months. The partnership provides Avacta with a low risk route to CE marking our rapid antigen test during Q1 ahead of achieving our own ISO13485 accreditation.'
If the situation had changed then surely a new RNS would be required. The only slight concern I have is whether there would be a possibility Mologic would have a conflict of interest but I have no knowledge in this field. The drop is sharp enough to imply it is related to the Aptamer news but due to the wild increases in SP recently a correction was expected without news.
I will continue holding.
Spinnaker
Officemanager
I am not surprised you thought my post was a poor de-ramping post. That is most probably because it was not the purpose to de-ramp. I speak merely as a shareholder having bought at 5.2 down to 1.95p. I bought a pack to try them. My comments about heavy breathing were obviously tongue in cheek but with a serious slant.
Most people will not wear a mask for 7 hours straight since they will need to eat and drink during that time. In hospitals for instance each time a mask is taken off it is thrown away. I assume therefore the intention is that this mask will retain its anti viral properties through several on/off cycles. However a shift would typically be 12 hrs and for more than 7 hours of that a mask may need to be worn. There is no information on the packaging as to how much reduction of anti-viral properties there is over time either in storage or in use or in differing throughputs of inhaled or exhaled air.
I have some experience of solid copper as a biocide and its effective life is quite extended. I comprehend that very small particles are effective in a mask and that due to the tiny (nano) size the effective life will be less since the surface area is huge relative to the mass. There will be oxidation and other chemical reactions on the surface which will limit the effective life. Because of this I was surprised that the individual masks were not in sealed packaging to prevent air access and thus reduction of efficacy over time.
I do not work in an environment where I need to wear a mask the whole time. Therefore I am interested whether the 7 hour time limit could be spread over several days for instance.
A link to the lab testing regime and results would be useful if you could please post.
Many thanks
Spinnaker
Please post a link to the testing details so we can see
Dippfs
It looks like the US govt. are paying $210m for 500,000 doses which would equate to $410 per dose. Does everyone agree? The price may be below market since the US govt. contributed cash towards the development and testing of this product.
I don't think this order extension necessarily implies any knowledge of Activ 2 progress on this drug that we don't know. It is more a case of the US govt. covering the bases. They wouldn't want AZN selling to other countries on approval without getting first dibs. This is particularly so since the govt. contributed to the final development.
This is an extension of the agreement made last year and effectively exercises the option the US held to increase the number of doses for the US. The agreement is subject to EUA being achieved.
I didn't see any reference to whether the I/M or I/V treatment is ordered. I think this omission lends strength to my suggestion that the U.S. govt. do not have inside info.
Exciting times.
Spinnaker
I have received mine and they fit pretty well. Not individually wrapped so not clear when the 7 hours runs from. Do they last longer if you breathe less frequently than usual or aren't in a Covid laden atmosphere! I can't find any details of the testing regime.
By the way my glasses were misting up badly today trying to look at some plans with an architect.
Well it sounds as though they have sold a few to shareholders anyway. That's some good news.
Spinnaker
Mafioso
Watch out for SAE. The reason it has dived down is concern about Guptsa related financing. I had been in for ages but got out a week or so ago at 12.5 on a big loss.
Spin
Can't spell my name!
I took a small position here a few weeks ago after it appeared on Zak Mir's list. I think I am in at 10p ish so looking good so far. It went down quite a bit after I bought but been on the up recently. The plan seems to be to buy into a battery/industry metals miner that is close to production but no news yet on any targets as far as I know but not done any recent research.
A lifelong miner following his dream and doing it himself,as far as I can see.
ATB.
Spinnalker
Thanks 1509
Tried one of the masks today. Not individually sealed so if the anti-viral only lasts 7 hours the whole box will be run out of time by now. Interested in your thought that lab time was limited. I find that odd since the sales benefit of being able to advertise 12 hours or more would have been great.
Anyway, a reasonable fit for me as long as keep my mouth closed. If I open it too far the mask tends to either slide down the nose or off the chin. Not too difficult to breathe but definitely restrictive and impossible to wear glasses without them steaming up. That is very frustrating but I've found the same with every mask I have worn.
Good luck all.
Spin
I do agree with you db66. I can understand that GPs and most hospital doctors are not keeping up with the number of various potential treatments and trials that are in process and the methods of application but as you say the decision makers and researchers should be on the ball. To be fair, normal hospital doctors and GPs will really only focus on approved treatments . They have more important stuff to do trying to keep patients alive from day to day and it is not their role to keep tabs on every bit of research.
I am sure Fauci and Topol and an increasing number of others are and will be in due course. I'm not too sure if Horby is looking at Synairgen's progress every day but he won't be able to ignore it if the current trials repeat July P2 results. The proof of the pudding is in the eating and a successful P2 and roll on to P3 in Active 2 with simultaneous application for EUA will be the making of Synairgen and will be front page news in UK.
Best of luck to all.
Spinnaker
Joey, well done finding that. A fantastic link. I found it fascinating although lots was well over my head.
I was surprised that there was not more differentiation made between I/V interferon trials and the inhaled version . Akiko Iwasaki was clear that there were fairly severe side effects and even adverse effects when administered to severely ill patients and she mentioned one cohort where a very high percentage were also receiving cortocosteroids in a trial. I assume this was the WHO trial. Her take was that interferons may not mix well with corticosteroids and also that late treatment may be adverse.
I understood that Synairgen's treatment was still effective when co-dosing with steroids shown in P2 trial and also that the short ACE form recently found gave a scientific reason why SNG001 also seemed to work in more severely ill patients and not have the adverse effect shown in the WHO trial for I/V and S/C interferon Beta1a
I wonder if perhaps Akiko Iwasaki was not aware of the Southampton research published in Nature in Jan 21 regarding the short form ACE receptors. https://www.nature.com/articles/s41588-020-00759-x
One thing I don't quite understand is whether the short form ACE findings imply any bearing on mode of administration ie Nebulised or I/V likely to succeed or timing of treatment.
Can anyone explain to me please?
Many thanks
Spinnaker
I have written to the company to suggest they approach the ACTIV-2 trials organisers to see if Foralumab could be included in that trial regime. The best things are it should be swift and paid for by US government. If, however, the company cannot show that adequate production can be or is being ramped up I would give them little chance of acceptance. Synairgens SNG001 has now been accepted onto the trial and first patient dosed on 'at home' P2.
You will not be surprised that I have not had the courtesy of a reply to my email.
Best wishes
Spinnaker
I just bought some of the masks on Amazon and received them today, one day later. Not out of the box yet. I am a bit concerned what the 7 hour use is based on. If it is copper surely that won't deteriorate quickly, I mean it's not as though it has a half life of a few hours. I suppose the copper could oxidise and reduce efficiency but if so that would start happening as soon as oxygen got into the product. I will check if they are packaged individually in sealed bags tomorrow.
TBH I was spiked on this share and still holding reasonable paper loss but think the management have shown themselves incompetent at best so far although I understand there are new faces there. I do not have enough confidence to average down any more. Will hold for a bit to see if any sales news.
Spinnaker
Thanks for that Prion
Yes I had read about the short form ACE and how that gave a scientific basis for the SNG001 treatment not promoting cytokine storm during P2 hospital trials. It just seems odd that this wasn't referenced in the paper just published. Also that there was no differentiation between INFa and INFb let alone b1a /b1b. I must admit I haven't read it thoroughly and it is no doubt above my head.
To be honest I don't really know the difference between INFb and INFa except that they are both type 1 interferons. It does look as though there are loads of different interferons all of which have a role to play in our immune system and I understand that SNG have hit on B1a to be the most important or most likely to be efficacious as a treatment. This seems to be supported by most of the documents I have read. I can see though that the current fashion is to give multiple products at the same time (****tails) and of course the logistics of trialing this approach with interferons will take years. I am satisfied that as far as the research I have done Synairgen's approach should be good, appropriate and protective against hospitalisation, severe disease/death and also long Covid. I do have trust that Prof Holgate and others know what they are doing from a scientific point of view. A plus would be commercial success and use against flu and other respiratory viruses in the future for COPD, asthma and people with other co-morbidities.
I am still very excited about the prospects for this product and the share value but a bit concerned that the number of competing treatments for trials may delay trial completions and authorisation.
All the best
Spin